证券日报网讯12月8日，长虹美菱（000521）在互动平台回答投资者提问时表示，公司是国家级技术创 新标杆企业，以技术创新和产品创新精心打造企业核心竞争力。经过40多年的发展，公司从单一的冰箱 品类到构建完成冰箱(柜)、空调、洗衣机、厨大电、小家电和生物医疗低温存储设备等多品类协同发展 的新格局。公司凭借尖端研发团队及先进的技术积淀，使美菱在智能、保鲜、薄壁、净味、节能、风 冷、深冷、仿真、超薄、洗净、护衣等多个领域不断取得突破性成果。近年来，公司先后荣获"智慧冰 箱智能制造试点示范项目""国家级绿色工厂""全国家电行业质量领先企业""国家技术创新示范企业""中 国产学研合作创新示范企业"等多项国家级荣誉称号。2025年以来，工信部公示首批中国消费名品名 单，长虹美菱成功入选。同时，公司凭借强大的创新力、产品力、品牌力获得了多项技术和产品创新荣 誉，多款美菱产品屡次斩获多项国内大奖，不断彰显美菱智能创新技术的能力与实力。未来，公司将继 续聚焦主营业务，坚持以用户需求为导向、以技术创新为牵引，以增强市场竞争力，实现可持续发展。 ...

Core Viewpoint - The article highlights the increasing attention from institutions towards companies in the high-end manufacturing sector, particularly in the fields of industrial machinery and electronic equipment, as evidenced by the recent institutional research on 37 companies in the Beijing Stock Exchange [2]. Group 1: Institutional Research Focus - In October, 37 companies on the Beijing Stock Exchange underwent institutional research, with a significant focus on the industrial machinery and electronic equipment sectors, involving 8 and 7 companies respectively [2]. - Notable companies under research include Tonghui Electronics, which specializes in electronic measurement instruments, and BiKang Instruments, focused on marine economic monitoring [2]. Group 2: Characteristics of Researched Companies - The researched companies exhibit three main characteristics: 1. Significant technical barriers, such as Tonghui Electronics with a domestic market share of 25% in electronic measurement instruments, and Chuangyuan Xinke with a 70% market share in 6G testing equipment [2]. 2. Differentiated growth potential, with Tonghui Electronics reporting a 59.36% increase in net profit for the first three quarters, while Zhongke Meiling faces cash flow pressure due to rising accounts receivable [3]. 3. Dual drivers of policy and demand, with sectors like semiconductors, renewable energy, and biomedicine experiencing explosive downstream demand supported by domestic substitution policies [3].

Core Viewpoint - Haier Biomedical is a leading enterprise in the global biomedical low-temperature storage sector, focusing on the research, production, and sales of biomedical low-temperature storage equipment, with a full industry chain and technological barriers as its competitive advantages [1] Financial Performance - For Q3 2025, Haier Biomedical reported revenue of 1.761 billion yuan, ranking 9th out of 42 in the industry, with the top competitor, Mindray Medical, generating 25.834 billion yuan [2] - The net profit for the same period was 202 million yuan, placing the company 8th in the industry, while the industry leader, Mindray Medical, achieved a net profit of 7.814 billion yuan [2] Financial Ratios - As of Q3 2025, Haier Biomedical's debt-to-asset ratio was 18.85%, lower than the industry average of 27.21%, indicating strong solvency [3] - The gross profit margin was 46.51%, down from 48.51% year-on-year and below the industry average of 48.67%, suggesting a need for improvement in profitability [3] Management and Shareholder Structure - The chairman, Tan Lixia, has a rich background, while the general manager, Liu Zhanjie, saw a salary decrease from 2.3883 million yuan in 2023 to 2.295 million yuan in 2024 [4] - As of September 30, 2025, the number of A-share shareholders increased by 3.39% to 13,200, with an average holding of 24,000 circulating A-shares, a decrease of 3.28% [5] Business Highlights and Future Outlook - The company is expected to see improved performance as the industry recovers, with new industries contributing to growth, a market share of over 50% in plasma collection solutions, and strong overseas performance in 17 countries [5] - Forecasts for net profit from 2025 to 2027 are 420 million, 510 million, and 590 million yuan, with corresponding P/E ratios of 25, 21, and 18 [5] - The company is also focusing on low-temperature storage business recovery, laboratory solutions, and innovative medical solutions, indicating a positive outlook for H2 2025 [6]

Core Viewpoint - Zhongke Meiling's stock price increased by 2.47% to 21.98 yuan, indicating positive market sentiment towards the company [1] Company Performance - Zhongke Meiling reported a revenue of 150 million yuan for the first half of 2025, representing a year-on-year growth of 2.16% [1] - The net profit attributable to shareholders reached 11.0458 million yuan, showing a year-on-year increase of 5.94% [1] - The company's non-recurring net profit was 6.8064 million yuan, which reflects a significant year-on-year growth of 158.29% [1] Industry Position - Zhongke Meiling operates in the specialized equipment manufacturing sector and is recognized as a national-level "little giant" enterprise focusing on specialized and innovative technologies [1] - The company specializes in the research and manufacturing of biomedical low-temperature storage equipment, providing solutions for medical and scientific research fields [1]

Company Overview - Haier Biomedical focuses on the research, production, and sales of biomedical low-temperature storage equipment, providing digital scene solutions in life sciences and medical innovation [2] - The company serves a wide range of users, including hospitals, biopharmaceutical companies, research institutions, disease control centers, and blood stations, offering comprehensive solutions centered around smart laboratories and digital hospitals [2] - Haier Biomedical has established partnerships with over 40 international organizations, including WHO and UNICEF, and its products are applied in more than 130 countries and regions globally [2] Financial Performance - As of the latest quarterly report for 2024, the company achieved a revenue of 1.782 billion yuan, a year-on-year decrease of 2.43%, and a net profit of 309 million yuan, down 13.45% year-on-year, with a gross profit margin of 48.51% [2] - The company's stock closed at 33.78 yuan, with a rolling price-to-earnings (PE) ratio of 29.29 times and a total market capitalization of 10.740 billion yuan [1] Industry Comparison - The average PE ratio for the medical device industry is 44.91 times, with a median of 31.89 times, positioning Haier Biomedical at the 69th rank within the industry [1][3] - The company has a lower PE ratio compared to the industry average, indicating potential undervaluation relative to its peers [3] Shareholder Information - As of September 30, 2024, Haier Biomedical had 12,200 shareholders, an increase of 1,510 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares per shareholder [1]